The global diabetes drugs market size was valued at USD 79.25 billion in 2023 and is projected to grow from USD 89.39 billion in 2024 to USD 153.98 billion by 2032, exhibiting a CAGR of 7.0% during the forecast period (2024-2032).Key insights into this growing market have been shared by Fortune Business Insights in its report, titled “Diabetes Drugs Market Size, Share and Global Trend By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Geography Forecast till 2026”.

The report comprehensively analyses the major factors that will influence the growth of the market. Diabetes is a chronic disease in which a person’s blood sugar or blood glucose gets too high. This glucose gets absorbed in the body through a hormone called insulin which is made in the pancreas. Insulin helps glucose enter the body’s cells, which, in turn, give the body energy to function. When the body does not make enough insulin or fails to make any insulin at all, a person becomes diabetic. The disease has no cure and can cause major health problems with age. Diabetes drugs are the medication that an affected person has to consume to regulate her glucose levels.

Rising Number of Type 2 Diabetes Cases to Fuel the Market

Diabetes has various forms and the most prevalent ones include Type 1 (body fails to make any insulin), Type 2 (body does not make enough insulin), gestational (develops in pregnant women), and monogenic (rare genetic form of diabetes). Type 2 diabetes is the most common form of diabetes as it develops during middle age. The global diabetes drugs market is expected to grow considerably as Type 2 diabetes becomes even more widespread. Increasing sedentary lifestyle, rising stress levels, lack of exercise leading to obesity, and unhealthy food habits are the factors cited for the growth of the market.

Undiagnosed Sections May Hinder Market Growth

The Centers for Disease Control and Prevention has revealed that around 7.2 mn people in the US remained undiagnosed in 2017. The global diabetes drugs market may see restrained growth as a result, since a large number of people remain untapped.

However, as lifestyles get more sedentary and diagnostic methods get more advanced, the market is sure to gain momentum between 2018 and 2026 and register a CAGR of 6.1%.

Rising Demand for Insulin Treatments to Surge the Market

Insulin provides the one of the most efficient treatment methods for diabetes. As a result, there is a growing demand for low-cost insulin treatments, especially to combat Type 2 diabetes. The rapidly rising insulin segment is, therefore, expected to boost the global diabetes drugs market during the forecast period. This has also encouraged private and public investments in research and development, which, in turn, will accelerate market growth. For example, recently, a rapid-acting, low-cost insulin called Lispro was launched in its generic form by Eli Lilly and Company in the US.

Market Competition Set to Intensify

Key players are increasing their investments in research and development activities and launching new products to maintain their competitive edge. For example, in July 2019, the National Institute for Health and Care Excellence cleared Forxiga for treating Type 1 diabetes in England and Wales. The drug has been developed jointly by Bristol-Myers Squibb and AstraZeneca. The global diabetes drug market is expected to grow as a result.

Fortune Business Insights identifies some key players in the market which include Johnson and Johnson Services, Eli Lilly and Company, AstraZeneca, Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Sanofi, and a few others.

North America Expected to Dominate the Market

North America is expected to hold a large chunk of the market share in the forecast period. This evaluation is based on the region’s revenue generation of US$ 23,965.5 Mn in 2018. Moreover, rising prevalence of diabetes in the US is encouraging companies to develop novel and affordable drugs for the patients. Growing awareness among the people regarding diabetes and anti-diabetic drugs in North America will aid growth of the global diabetes drugs market. North America is expected to be followed by Europe in terms of market share and revenue generation during the forecast period.

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower, Baner-Mahalunge Road,
Baner, Pune-411045, Maharashtra, India.

Phone:
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: [email protected]

Fortune Business Insights™

Linkedin | Twitter | Blogs

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]